Novartis’ Promacta gets FDA breakthrough designation for severe aplastic anemia

This article was originally published here

Novartis’ drug Promacta (eltrombopag) has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for first-line treatment of severe aplastic anemia (SAA).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply